Novel pyrido [2,3-f][1,4] thiazepines and pyrido [3,2-b][1,5] benzothiazepines

Abstract: Novel pyrido[2,3-f][1,4]thiazepines and novel pyrido[3,2-b][1,5]benzothiazepines are described. These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. Also described are methods of producing the novel compounds and intermediates thereof.

Description: BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to novel pyrido[2,3-f][1,4]-thiazepines and novel pyrido[3,2-b][1,5]benzothiazepines. These compounds are inhibitors of calcium ion uptake into smooth muscle tissue, and act to relax or prevent contraction of the tissue mediated by calcium mechanisms. The compounds are active antihypertensives and bronchodilators. These compounds are useful for the treatment of cardiovascular disorders, including hypertension, ischemia, angina, congestive heart failure, migraine, myocardial infarction and stroke. The compounds are also useful for the treatment of other disorders such as hypersensitivity, allergy, asthma, dysmenorrhea, esophageal spasm, gastrointestinal motility disorders, glaucoma, premature labor and urinary tract disorders. The present invention also relates to a process for preparing these compounds, compositions thereof, methods of use and novel intermediates. 2. Related Disclosure United States Patent No. 4,285,955 and United States Patent No. 4,483,985 (which is a divisional of the aforementioned patent) disclose acyclic sulfone substitution on simple dihydropyridines which possess calcium channel antagonist activity. However, the compounds in question are chemically distinct from the compounds of the present invention. DE-A-2815088 describes pyrido-[3,2-b][1,5]benzothiazepines which are substituted with a 1-piperazinyl group at the 5 position of the thiazepine ring. The compounds are stated to be useful as antihistamines, orexigenics and antianaphylactics. FR-A-2511683 describes pyrido-[3,2-b][1,5]benzothiazepines similar to those of DE-A-2815088, wherein the 1-piperazinyl group is substituted at its 4 position with a carbonyl group or a thiocarbonyl group. Preferred carbonyl groups are alkoxycarbonyl groups. The compounds are stated to be non-orexigenic antihistamines and antianaphylactics. Mannhold et al . in Pharmazie Heute vol. 3 (104), pages 139-147 (1983) describe a study of structure-activity relationships in calcium antagonists, including 1,4-dihydropyridine derivatives. They determined that the following features are essential for calcium antagonist activity in 1,4-dihydropyridine derivatives:(1) a dihydropyridine ring, (2) a secondary nitrogen at the 1 position of the dihydropyridine ring, and (3) a bulky substituent at the 4 position of the dihydropyridine ring. They also determined that the presence of ester groups at the 3 and 5 positions of the dihydropyridine ring in calcium antagonists such as Nifedipine is not essential for the calcium antagonist activity. EP-A-0225175 describes 1,4-dihydropyridine derivatives useful as calcium antagonists. The principal characterising feature of these derivatives is the presence of a 5 or 6 membered unsaturated nitrogen containing ring which is optionally substituted and/or optionally fused to a phenyl ring, and which is coupled to the 2 position of the 1,4-dihydropyridine ring through a methyleneoxy, methylene amino, methyleneimino, methylenethio or methylenesulfoxy group. 10-Phenyl-2H-thiopyranol[3,2-b]quinolines are disclosed in Pagani, G.P.A., J. Chem. Soc., Perkin Trans. 2 , 1392 (1974). However, these compounds are not calcium channel antagonists. United States Patent No. 4,532,248 discloses a broad genus of dihydropyridines, including cyclic sulfones fused to a dihydropyridine nucleus. Cardiotonic activity is claimed for the entire genus. The compounds of the present invention, on the other hand, are potent calcium antagonists with pharmacologic activity opposite to that claimed in United States Patent No. 4,532,248. SUMMARY OF THE INVENTION The present invention is directed to pyrido[2,3-f][1,4]thiazepines and pyrido[3,2-b][1,5]benzothiazepines of the general formula where Y and Z may be CH₂, or together Y and Z may form a fused phenyl ring; R₁ may be hydrogen, amino, C₁-C₈ straight or branched chain alkyl, trifluoromethyl or alkoxymethyl; R₂ may be C₁-C₈ straight or branched chain alkyl, benzyl, 3-piperidyl, N-substituted 3-piperidyl, N-substituted 2-pyrrolidinyl methylene or substituted alkyl; wherein said N-substituted 3-piperidyl and said N-substituted 2-pyrrolidinyl methylene may be substituted with C₁-C₈ straight or branched chain alkyl or benzyl, and said substituted alkyl may be substituted with C₁-C₈ alkoxy, C₂-C₈ alkanoyloxy, phenylacetyloxy, benzoyloxy, hydroxy, halogen, p -tosyloxy, mesyloxy, amino, carboalkoxy or NR₅R₆; R₃ may be 2-pyridyl, 3-pyridyl, 2-thienyl, 3-thienyl, 2,1,3-benzoxadiazolyl, 2,1,3-benzthiadiazolyl or substituted phenyl; wherein said substituted phenyl may be substituted at any of positions 2-6 with hydrogen, C₁-C₈ straight or branched chain alkyl, C₁-C₈ alkoxy, cyano, C₁-C₄ carboalkoxy, C₁-C₈ alkylthio, difluoromethoxy, difluoromethylthio, C₁-C₈ alkylsulfonyl, halogen, nitro or trifluoromethyl; R₄ may be hydrogen, C₁-C₈ straight or branched chain alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, substituted benzyl, formyl, acetyl, t -butyloxy carbonyl, propionyl, substituted alkyl or R₇CH₂C=O; wherein said substituted benzyl may be substituted with halogen, trifluoromethyl, C₁-C₈ straight or branched chain alkyl or C₁-C₈ alkoxy, and said substituted alkyl may be substituted with amino, C₁-C₄ dialkyl amino, C₁-C₈ alkoxy, hydroxy or halogen; R₅ and R₆ may be the same or different and may be hydrogen, C₁-C₈ straight or branched chain alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, phenethyl or R₅ and R₆ together may form a heterocyclic ring selected from the group consisting of piperidino, pyrrolidino, morpholino, thiomorpholino, piperazino or an N₄-substituted derivative of piperidine; wherein said N-substituted heterocyclic ring may be substituted with hydrogen, C₁-C₈ straight or branched chain alkyl, benzyl, benzhydryl, phenyl or substituted phenyl; wherein said substituted phenyl may be substituted with hydrogen, C₁-C₈ alkoxy, halogen, C₁-C₈ straight or branched chain alkyl, nitro or trifluoromethyl; R₇ may be amino, C₁-C₄ dialkyl amino, C₁-C₈ alkoxy, hydroxy or halogen; and optical antipodes (enantiomers or diasteriomers) or pharmaceutically acceptable salts thereof such as salts of organic and inorganic acids such as hydrochloric, hydrobromic, fumaric, maleic, p -toluene sulfonic, methyl sulfonic acid and the like. Also included in this invention is a process for preparing the compounds described above, said process disclosed in detail hereinafter. A further part of the present invention are certain intermediates and the process for the preparation thereof. The compounds of the above formula inhibit the uptake of calcium ions into smooth muscle, and therefore act to relax or prevent calcium ion-mediated contraction of smooth muscle tissue. These compounds are useful for the treatment of cardiovascular disorders, including hypertension, ischemia, angina, congestive heart failure, myocardial infarction and stroke. The compounds are also useful for the treatment of other disorders such as hypersensitivity, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, gastrointestinal motility disorders, glaucoma, premature labor and urinary tract disorders. DETAILED DESCRIPTION OF THE INVENTION The invention in its broadest aspects relates to pyrido[2,3-f][1,4]thiazepines and pyrido[3,2-b][1,5]benzothiazepines which inhibit the uptake of calcium ions into smooth muscle tissue. The compounds which possess this activity are shown in the formula above. The preferred compounds of the present invention are those in which R₁ is methyl: R₂ is ethyl or substituted C₁-C₈ alkyl wherein the substituent is acetoxy, amino or NR₅R₆ wherein R₅ and R₆ are as previously defined; R₃ is substituted phenyl; R₄ is hydrogen, C₁-C₈ straight or branched chain alkyl, benzyl, formyl, R₇CH₂C=O or t-butyloxy carbonyl; R₇ is amino; and the optical antipodes (enantiomers or diastereoisomers) or the pharmaceutically acceptable salts thereof. Particularly, the preferred compounds of the present invention are: 1. 2-(N-benzyl-N-methylamino)ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methyl-pyrido[2,3-f][1,4]thiazepine-8-carboxylate; 2. 2-(N-benzyl-N-methylamino)ethyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9- hexahydro-pyrido[2,3-f][1,4]thiazepine-8-carboxylate; 3. Ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methyl-pyrido[2,3-f][1,4]thiazepine-8-carboxylate; 4. Ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-4-ethyl-2,3,4,5,6,9-hexahydro-7-methyl-pyrido[2,3-f][1,4]-thiazepine-8-carboxylate; 5. Ethyl 9-(2,3-dichlorophenyl)-4,7-dimethy-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f][1,4]thiazepine-8-carboxylate; 6. Ethyl 4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydro-9-(2,3,4,5,6-pentafluorophenyl)-pyrido[2,3-f][1,4]-thiazepine-8-carboxylate; 7. Ethyl 1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methyl-9-(2,3,4,5,6-pentafluorophenyl)-pyrido[2,3-f][1,4]-thiazepine-8-carboxylate; 8. Ethyl 1,1-dioxo-4-ethyl-2,3,4,5,6,9-hexahydro-7-methyl-9-(3-nitrophenyl)-pyrido[2,3-f][1,4]-thiazepine-8-carboxylate; 9. Ethyl 4-(2,3-dichlorophemyl)-5,5-dioxo-10-formyl-2-methyl-1,4,10,11-tetrahydropyrido[3,2-b][1,5]-benzothiazepine-3-carboxylate; 10. 2-Acetoxyethyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f][1,4]-thiazepine-8-carboxylate; 11. 2-Pivaloyloxyethyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f][1,4]thiazepine-8-carboxylate; 12. Ethyl 4-(2,3-dichlorophenyl)-2,10-dimethyl-5,5-di oxo-1,4,10,11-tetrahydropyrido[3,2-b][1,5]-benzothia-zepine-3-carboxylate; 13. 2-(N-benzyl-N-methylamino)ethyl 4-(2,3-dichlorophenyl)-2,10-dimethyl-5,5-dioxo-1,4,10,11-tetrahydro-pyrido[3,2-b][1,5]benzothiazepine-3-carboxylate; 14. 2-(N,N-dibenzylamino)ethyl 4-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydro-pyrido[2,3-f][1,4]thiazepine-8-carboxylate; 15. 2-(N-benzyl-N-methylamino)ethyl 4-(2,3-dichlorophenyl)-4-ethyl-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methyl-pyrido[2,3-f][1,4]thiazepine-8-carboxylate; and 16. (N-benzyl-2-pyrolidinyl)methyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f][1,4]thiazepine-8-carboxylate. The compounds of the present invention in which Y and Z are CH₂ (i.e. pyrido[2,3-f][1,4]thiazepines) are prepared as shown in Scheme I below. The thiazepinone (6) is a key intermediate in the synthesis of some dihydropyridines and was prepared in the following manner. Reaction of the BOC protected cystamine (1) (available in two steps as shown above, and described in Examples 1 and 2) with epichlorohydrin followed by cyclization of the intermediate chlorohydrin (2) resulted in thiazepinol (4). Cyclization of chlorohydrin (2) proceeds through epoxide (3). Nucleophilic attack by the carbamate anion opens the epoxide from the less hindered side resulting in formation of the thiazepinol (4). The intermediate epoxide (3) can be isolated if only 1 equivalent of base is used, or the chlorohydrin (2) can be cyclized directly to (4) by the addition of 2 equivalents of base. Thiazepinol (4) was oxidized first with m -chloroperoxybenzoic acid to obtain 1,1-dioxo-thiazepinol (5) which was then oxidized with Jones reagent to obtain the 1,1-dioxothiazepinone (6). The ketosulfone (6) was then reacted with an appropriately substituted aldehyde and substituted 3-aminoacrylate derivatives to obtain the dihydropyridines (7). The t -butyloxy protecting group was removed by exposure of the dihydropyridine (7) to acidic conditions to yield (8). The free amino functionality of (8) can then be alkylated by benzyl bromide or substituted benzyl bromides to give (9) (where Z=halo, alkyl alkyloxy, alkoxy, nitro, or trifluoromethyl), or reductively aminated with aldehydes or ketones to give (10) (where X₁ and X₂ are hydrogen, alkyl, cycloalkyl or together form a homocyclic or heterocylic ring). Additionally, the amine (8) can be acylated using various carboxylic acids (where X₃ is hydrogen, alkyl, amino, disubstituted amino, alkoxy, hydroxy or halogen) to give the amides (11a) which can then be reduced to the corresponding amines (11b). In the case where an alkoxy group is present on the ester side chain as in (12), it can be acylated and the t -BOC protecting group can be removed to give the compound (13) which can be benzylated, alkylated or acylated in a manner analogous to (8). The compounds of the present invention in which Y and Z together form a phenyl ring (i.e. pyrido[3,2-b][1,5]benzothiazepines) are prepared as shown in Scheme 2 below. 1,1-Dioxo-benzothiazepenone (15) is prepared in three steps from known benzothiazepinone (14) as shown and as described by Federsel, H.J. et al., Tetrahedron Letters 21 , 2429 (1980). The dihydropyridine (16) is prepared by reacting (15) with the appropriate aldehyde and substituted 3-aminoacrylate. Pharmaceutical compositions containing a compound of the present invention as the active ingredient in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, hinders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The compounds may also be administered in the form of an aerosol. The pharmaceutical compositions will generally contain per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, from about 0.001 to about 100 mg/kg, and preferably from about 0.001 to about 20 mg/kg of the active ingredient. The following examples describe the invention in greater particularity and are intended to illustrate but not limit the invention. Example 1 Bis-N-(t-Butyloxycarbonyl)-cystamine A mixture of cystamine dihydrochloride (46.95 g, 0.285 moles) in 1 L THF and sodium hydroxide (33.33 g, 0.833 mole) in 500 mL of water was treated with di- t -butyldicarbonate (100.0 g, 0.458 mole) and stirred at room temperature for 2 hours. The aqueous phase was separated and extracted with 2 X 500 mL of ether. The combined organic phases were dried with brine and MgSO₄ and evaporated under reduced pressure to afford the product as a white solid (78.2 g, 78% yield) D.C.I.M.S. (M+H) 325. Example 2 N-(t-Butyloxycarbonyl)-2-aminoethanethiol A solution of his N-( t -butyloxycarbonyl)-cystamine (77.37 g, 0.220 mole) from Example 1, in 1 L of ethanol was treated with NaBH₄ (32.5 g, 0.859 mmole). Vigorous gas evolution ensued and subsided in 40 minutes. The reaction was stirred for an additional half hour and was poured into 2.5 L of a cold dilute solution of citric acid (pH 6). The mixture was then extracted with 3 x 1L of chloroform. The combined organic extracts were dried with MgSO₄ and the solvents were removed under reduced pressure. The resulting residue was distilled (66°-73°C 0.25 torr) to obtain the product (41.5 g, 53% yield). Example 3 (2-(t-Butyloxycarbonyl-amino)-ethyl)-(3-chloro-2-hydroxypropyl)-thioether N-( t -butyloxycarbonyl)-aminoethanethiol (40 g, 225 mmole) from Example 2, and epichlorohydrin (35.4 g, 383 mmole) in 300 mL of ethanol were cooled to O°C and treated with potassium carbonate (35.4 g). The reaction was warmed to room temperature over 90 minutes and filtered through celite. The volatiles were removed under reduced pressure to give a clear oil (62.09 g, 100% yield) D.C.I.M.S. 270(M+H). Example 4 4-N-(t-Butyloxycarbonyl)-6-hydroxy-2,3,4,5,6,7-hexahydro-1,4-thiazepine (2-( t -Butyloxycarbonyl-amino)-ethyl)-(3-chloro-2-hydroxypropyl)-thioether (30 g, 111.52 mmole) from Example 3, was dissolved in dimethylformamide (500 mL) at 0°C and treated with sodium hydride (9.81 g, 245 mmole) in 3 portions over 15 minutes. The reaction was allowed to warm to room temperature over 1 hour and 15 minutes, poured into 2.5 L ice water and extracted with 3 x 1 L chloroform. The combined organic extracts were dried with brine and Na₂SO₄, evaporated, and the resulting residue chromatographed (3:1 hexane:ethyl acetate, silica gel) to obtain the product as a white solid (12.47 g, 48% yield) D.C.I.M.S. 234(M+H) M.P. 80-82°C. Example 5 A solution of 4-N-( t -butyloxycarbonyl)-6-hydroxy-2,3,4,5,6,7-hexahydro-1,4-thiazepine (11.7 g, 50.6 mmole) from Example 4, in 100 mL of chloroform was added in a dropwise manner to a solution of m -chloroperbenzoic acid (19.2 g, 111 mmole) in chloroform (130 mL) over 1 hour. After the addition was complete, the reaction was stirred at ambient temperature for 2 hours. The reaction mixture was filtered and the filtrate concentrated under reduced pressure. The resulting residue was recrystallized from ethyl acetate-hexane to give the product (11.37 g, 85%) D.C.I.M.S. 266(M+H) M.P. 123-124°C. Example 6 4-N-( t -Butyloxycarbonyl)-1,1-dioxo-6-hydroxy-2,3,4,5,6,7-hexahydro-1,4-thiazepine (10.0 g, 37.7 mmole) from Example 5, was dissolved in 110 mL of acetone, cooled to 0°C and treated with 18.8 mL of freshly prepared Jones reagent. The reaction was stirred at ambient temperature for three hours and then treated with 5 mL of methanol. After 15 minutes, the reaction was filtered through magnesium sulfate and the filtrate immediately concentrated. The residue was filtered through a pad of silica gel using 3:1 chloroform-ethyl acetate to obtain the product (9.67 g, 87%) D.C.I.M.S. 264(M+H) M.P. 172-173°C. Example 7 A mixture of 4-N-( t -butyloxycarbonyl)-1,1-dioxo-2,3,4,5,6,7-hexahydro-1,4-thiazepin-6-one (2.00 g, 7.60 mmole) from Example 6, 2,3-dichlorobenzaldehyde (1.33 g, 7.60 mmole) and ethyl 3-aminocrotonate (0.98 g, 7.60 mmole) was heated to reflux in 40 mL of ethanol for 24 hours. The ethanol was removed under reduced pressure and replaced with 85 mL of toluene. The mixture was heated to reflux for 2 hours, cooled to room temperature and filtered to obtain the product (2.45 g, 61%). Example 8 Ethyl 9-(2,3-Dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methylpyrido-[2,3-f][1,4]thiazepine-8-carboxylate A mixture of ethyl 9-(2,3-dichlorophenyl)-4-( t -butyloxycarbonyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methylpyrido[2,3-f][1,4]thiazepine-8-carboxylate (2.45 g, 4.6 mmole) from Example 7, in ethyl acetate (150 mL) was cooled to O°C and saturated with gaseous hydrogen chloride. The mixture was warmed to room temperature. The reaction was then again chilled to O°C and shaken with 200 mL of cold 4 N NaOH. The aqueous layer was separated and extracted with 2 x 100 mL of chloroform. The ethyl acetate layer was dried with brine and the combined organic extracts were dried over Na₂SO₄. The solvents were evaporated under reduced pressure and the residue triturated with ether to give the product (1.86 g, 94% yield). Example 9 Ethyl 9-(2,3-Dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido-[2,3-f][1,4]thiazepine-8-carboxylate A mixture of ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methylpyrido-[2,3-f][1,4]thiazepine-8-carboxylate (0.500 g, 1.16 mmole) from Example 8, in acetonitrile (10 mL) was treated with formaldehyde (0.240 g, 37% aqueous solution) and sodium cyanoborohydride (0.062 g, 1.16 mmole). After 15 minutes, 6 drops of AcOH were added and the reaction was stirred for 1 hour. Then, 30 mL of water were added and the reaction mixture was extracted with 3 x 40 mL of chloroform. The pH was adjusted to 8 after the first extract. The combined organic extracts were dried with brine and Na₂SO₄ and then treated with 3 mL of triethylamine. After standing for 1.5 hours, the volatiles were removed under reduced pressure and the residue chromatographed (silica gel, 1.5% MeOH, 0.1% NH₃ in CHC1₃) to obtain the product as an oil which solidified on triturating with ether (0.479 g, 92% yield). Example 10 Ethyl 4-N-Benzyl-9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methylpyrido[2,3-f][1,4]thiazepine-8-carboxylate A mixture of ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methylpyrido[2,3-f][1,4]-thiazepine-8-carboxylate (0.400 g, 0.92 mmole), benzyl bromide (0.190 g, 1.11 mmole), and potassium carbonate (0.213 g, 1.55 mmole) was heated in acetonitrile (10 mL) for 3 hours. The reaction was cooled, the solids filtered, and the solvent was evaporated under reduced pressure. The residue was then chromatographed (silica gel 2:1 hexane:ethyl acetate) to give the product which was crystallized from ether (0.313 g, 65% yield). Example 11 A mixture of 4-N-( t -butyloxycarbonyl)-1,1-dioxo-2 , 3,4,5,6,7-hexahydro-1,4-thiazepin-6-one (8.39 g, 31.9 mmole) from Example 6, 2,3-dichlorobenzaldehyde (5.58 g, 31.9 mmole) and 2-(N-benzyl-N-methylamino)ethyl 3-aminocrotonate (7.91 g, 31.9 mmole) were heated to reflux in 40 mL of ethanol for 17 hours. The reaction was cooled to room temperature, filtered, and the solid washed with 50 mL of ether to obtain the title compound (10.72 g, 50% yield) D.C.I.M.S. (M+H) 668. Example 12 2-(N-Benzyl-N-methylamino)ethyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-5a-hydroxy-2,3,4,5,6,9-hexahydro-7-pyrido-[2,3-f][1,4]thiazepine-8-carboxylate 4-N-( t -Butyloxycarbonyl)-1,1-dioxo-2,3,4,5,6,7-hexahydro-1,4-thiazepin-6-one (2.10 g, 3.2 mmole) from Example 6, was treated as in Examples 8 and 9 to obtain the product which was recrystallized from isopropanol (1.23 g, 70% yield). Example 13 Optical Resolution of Ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methylpyrido[2,3-f][1,4]-thiazepine-8-carboxylate Racemic ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methylpyrido[2,3-f][1,4]-thiazepine-8-carboxylate (2.41 g, 5.59 mmole) from Example 8, was dissolved in 100 ml of hot methanol. This solution was combined with D-dibenzoyl tartrate (2.10 g, 5.59 mmole), and the solvent was removed under reduced pressure. The residue was crystallized 3 times from ethyl acetate. The salt was converted to the free base by extraction of a chloroform solution of the salt with aqueous ammonia. [α] D = +7.7° (C, 0.41, CHCl₃). The (-) isomer was obtained in a similar fashion using L-dibenzoyl tartaric acid; [α] D = -8.0 (C, 0.40, CHCl₃). Example 14 5-N-Formyl-3-hydroxy-2,3,4,5-tetrahydro-[1,5]-benzothiazepine To a solution of 5-N-formyl-3-hydroxy-2,3,4,5-tetrahydro-[1,5]-benzothiazepin-3-one (0.480 g, 2.31 mmole) prepared as described by Federsel, H. J. et al. , Tetrahedron Letters 21 , 2229 (1986), in 10 mL of ethanol was added NaBH₄ (0.090 g, 2.38 mmole). The reaction was stirred at room temperature for 1 hour. The reaction was partitioned between a saturated NH₄Cl solution and chloroform. The organic layer was washed with water, brine and dried over MgSO₄. The solvents were removed under reduced pressure to give the product as an oil (0.452 g, 94% yield) D.C.I.M.S. 210 [M+H]. Example 15 1,1-Dioxo-5-N-formyl-3-hydroxy-2,3,4,5-tetrahydro-[1,5]-benzothiazepine A solution of m -chloroperoxybenzoic acid (0.946 g, 5.5 mmole) in 20 ml of chloroform was treated with 5-N-formyl-3-hydroxy-2,3,4,5-tetrahydro-[1,5]-benzothiazepine (0.450 g, 1.93 mmole) from Example 14, in 10 mL of chloroform. The reaction was stirred for 16 hours at room temperature and the solvents were removed under reduced pressure. The residue was triturated with 2 x 10 mL water and the water was evaporated to obtain the product (0.443 g, 95% yield) D.C.I.M.S. 242 [M+H]. Example 16 1,1-Dioxo-5-N-formyl-2,3,4,5-tetrahydro-[1,5]-benzothiazepine-3-one A solution of 1,1-dioxo-5-N-formyl-3-hydroxy-2,3,4,5-tetrahydro-[1,5]-benzothiazepine (0.443 g, 1.83 mmole) from Example 15, in 5 mL of acetone was treated with Jones reagent (0.54 mL, 1.40 mmole), and the solution was heated to reflux for 15 minutes. An additional 0.15 mL of Jones reagent was added and the reaction was heated for 20 minutes longer. The cooled solution was filtered through MgSO₄, and the solvents were removed under reduced pressure. The residue was triturated with chloroform and filtered. Evaporation of the filtrate afforded the product (0.418 g, 95% yield) D.C.I.M.S. 240 [M+H]. Example 17 Ethyl 4-(2,3-Dichlorophenyl)-5,5-dioxo-10-formyl-2-methyl-1,4,10,11-tetrahydropyrido[3,2-b][1,5]-benzothiazepine-3-carboxylate A solution of 1,1-dioxo-5-N-formyl-2,3,4,5-tetrahydro-[1,5]-benzothiazepin-3-one (0.410 g, 1.71 mmole) from Example 16, 2,3-dichlorobenzaldehyde (0.297 g, 1.71 mmole) and ethyl 3-aminocrotonate (0.219 g, 1.71 mmole) in 7 mL of ethanol was heated to reflux for 18 hours. The solvent was removed under reduced pressure and the residue was chromatographed (silica gel, 1:1 hexane:ethyl acetate) to obtain the product as an oil (0.75 g, 86% yield). The product was recrystallized from chloroform-ether. Example 18 A mixture of 4-N-( t -butyloxycarbonyl)-1,1-dioxo-2,3,4,5,6,7-hexahydro-1,4-thiazepine-6-one (9.06g, 34.5 mmole) from Example 6, 2,3-dichlorobenzaldehyde (6.03 g, 34.5 mmole) and 2-hydroxyethyl 3-aminocrotonate (5.00 g, 34.5 mmole) was heated to reflux in 200 mL of ethanol for 24 hours. The ethanol was removed under reduced pressure and the residue was heated in refluxing toluene for 2 hours. After cooling a precipitate was filtered to give 6.75 g of the title compound. Evaporation of the filtrate and chromatography (2.5:1, ethyl acetate:hexane) produced 3.78 g of product. Example 19 2-Acetoxyethyl 9-(2,3-Dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methylpyrido[2,3-f][1,4]thiazepine-8-carboxylate 2-Hydroxyethyl 4- t -butyloxycarbonyl-9-(2,3-dichlorophenyl)-1,1-dioxo-5a-hydroxy-2,3,4,5,5a,6,9,9a-octahydro-7-methylpyrido[2,3-f][1,4]thiazepine-8-carboxylate (0.500 g, 0.97 mmole) from Example 18, was dissolved in 5 mL of pyridine and 5mL of acetic anhydride, and stirred for 2 hours. The solvents were removed under reduced pressure, and the residue was slurried in 25 mL of ethyl acetate and cooled to 0°C, after which the mixture was saturated with gaseous HCl. After 90 minutes, the reaction was poured into 30 mL of 4H NaOH. The ethyl acetate layer was separated and dried with brine, and the aqueous layer was extracted with 2 x 30 mL of chloroform. The combined organic extracts were dried with sodium sulfate and evaporated, and the residue was chromatographed (2% methanol, 0.1% ammonia in chloroform, silica gel) to give the product as a white solid (0.351 g, 89% yield). Example 20 2-Acetoxyethyl 9-(2,3-Dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydro-pyrido[2,3-f][1,4]thiazepine-8-carboxylate A mixture of 2-acetoxyethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methyl-pyrido[2,3-f][1,4]thiazepine-8-carboxylate (0.880 g, 1.69 mmole) from Example 19, and 1 mL of 38% aqueous formaldehyde solution in 20 mL of acetonitrile was treated with sodium cyanoborohydride (0.070 g, 1.69 mmole). After stirring for 1 hour, 0.5 mL of acetic acid was added, and the reaction was stirred for another 2 hours. After the addition of 40 mL of water and adjustment of the pH to 9 with 6N sodium hydroxide, the reaction was extracted with 3 x 30 mL of chloroform. The combined organic extracts were dried with sodium sulfate, the solvent was removed under reduced pressure, and the residue was chromatographed (2% methanol, 0.1% ammonia in chloroform on silica gel) to obtain the title compound (0.743 g, 82%). The physical constants for these dihydropyridine examples as well as a number of additional representative compounds of the present invention are presented below in Table 1. Table 2, below, sets forth inhibition of nitrendipine binding as well as inhibition of calcium dependent smooth muscle contraction in terms of percent inhibition, for a number of representative compounds of the present invention. The assay for inhibition of nitrendipine binding is performed using the following procedure: Female, New Zealand white rabbits (1-2 kg) are sacrificed by cervical dislocation, and the heart is immediately removed, cleaned and chopped into small pieces. The tissue is homogenized in 5 x volume of 0.05M Hepes buffer, pH 7.4. The homogenate is centrifuged at 4000 x g for 10 minutes, and the supernatant is recentrifuged at 42,000 x g for 90 minutes. The resulting membrane pellet is resuspended (0.7 ml/g weight) in 0. 05M Hepes, pH 7.4 and stored at - 70°C until used. Each tube of the binding assay contains ³H-nitrendipine (0.05-0.50nM), buffer, membranes (0.10 ml), and test compound in a total volume of 1.0 ml. After 90 minutes at 4°C, the bound nitrendipine is separated from the unbound by filtration on Whatman GF/C filters. After rinsing, the filters are dried and counted in a liquid scintillation counter. Non-specific binding of ³H-nitrendipine (that amount bound in the presence of excess unlabelled nitrendipine) is subtracted from the total bound to obtain specifically bound radiolabeled nitrendipine. The amount of specifically bound nitrendipine in the presence of a test compound is compared to that amount bound in the absence of a compound. A percent displacement (or inhibition) can then be obtained. The test for inhibition of calcium dependent smooth muscle contraction is determined according to the following procedure: The trachea and the aorta from dogs sacrificed by excess KCl injection are stored overnight at 4°C in oxygenated Krebs-Henseleit buffer. Tracheal rings, one cartilage segment wide (5-10 mm), are cut starting from the bronchial end. Rings of aorta tissue of the same width are also prepared. After cutting the cartilage, the trachealis muscle tissue and the aorta tissue are suspended in oxygenated Krebs-Henseleit buffer at 37°C in a 25 ml tissue bath. After a 60-minute equilibration period, the tissues are challenged with 10 µM carbachol. After 5 minutes, the tissues are rinsed and allowed to rest 50 minutes. The tissues are then challenged with 50 mM KCl and, after 30 minutes, the contractions are quantitated. The tissues are then rinsed and reequilibrated for 50 minutes. Test compounds are then added for 10 minutes, and the tissue is rechallenged with 50 mM KCl. After 30 minutes, the contraction is recorded and used to determine the % inhibition of control. The percent inhibition of smooth muscle contraction is calculated from response data before and after drug treatment. A rating is assigned to the compound depending upon the percent inhibition obtained.

Claims: A compound of the formula where Y and Z are CH₂ or together Y and Z form a phenyl ring; R₁ is hydrogen, amino, C₁-C₈ straight or branched chain alkyl, trifluoromethyl or alkoxymethyl; R₂ is C₁-C₈ straight or branched chain alkyl, substituted alkyl, benzyl, 3-piperidyl, N-substituted 3-piperidyl or N-substituted 2-pyrrolidinyl methylene; wherein said N-substituted 3-piperidyl and said N-substituted 2-pyrrolidinyl methylene are substituted with C₁-C₈ straight or branched chain alkyl or benzyl, and said substituted alkyl is substituted with C₁-C₈ alkoxy, alkanoyloxy, aralkanoyloxy, aroyloxy, hydroxy, halogen, p -tosyloxy, mesyloxy, amino, carboalkoxy or NR₅R₆; R₃ is 2-pyridyl, 3-pyridyl, 2-thienyl, 3-thienyl, 2,1,3-benzoxadiazolyl, 2,1,3 benzthiadiazolyl or substituted phenyl; wherein said substituted phenyl is substituted at any of positions 2-6 with hydrogen, C₁-C₈ straight or branched chain alkyl, C₁-C₈ alkoxy, cyano, carboalkoxy, C₁-C₈ alkylthio, difluoromethoxy, difluoromethylthio, C₁-C₈ alkylsulfonyl, halogen, nitro or trifluoromethyl; R₄ is hydrogen, C₁-C₈ straight or branched chain alkyl, C₃-C₇ cycloalkyl, aryl, benzyl, substituted benzyl, formyl, acetyl, t -butyloxy carbonyl, propionyl, substituted alkyl or R₇CH₂C=O; wherein said substituted benzyl is substituted with halogen, trifluoromethyl, C₁-C₈ straight or branched chain alkyl or C₁-C₈ alkoxy, and said substituted alkyl is substituted with amino, dialkyl amino, C₁-C₈ alkoxy, hydroxy or halogen; R₅ and R₆ are the same or different and are hydrogen, C₁-C₈ straight or branched chain alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, phenethyl or R₅ and R₆ together are a heterocyclic ring selected from the group consisting of piperidino, pyrrolidino, morpholino, thiomorpholino, piperazino or an N-substituted derivative of said heterocyclic rings; wherein said N-substituted heterocyclic ring is substituted with hydrogen, C₁-C₈ straight or branched chain alkyl, benzyl, benzhydryl, phenyl or substituted phenyl; wherein said substituted phenyl is substituted with hydrogen, C₁-C₈ straight or branched chain alkyl, C₁-C₈ alkoxy, halogen, nitro or trifluoromethyl; R₇ is amino, dialkyl amino, C₁-C₈ alkoxy, hydroxy or halogen; and optical antipodes or pharmaceutically acceptable salts thereof. The compound of claim 1 wherein R₁ is methyl; R₂ is ethyl or substituted alkyl; R₃ is substituted phenyl; R₄ is hydrogen, C₁-C₈ straight or branched chain alkyl, benzyl, formyl, t -butyloxycarbonyl or R₇CH₂C=O; and R₇ is amino. The compound of claim 1 selected from the group consisting of a. 2-(N-benzyl-N-methylamino)ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methyl-pyrido[2,3-f][1,4]-thiazepine-8-carboxylate; b. 2-(N-benzyl-N-methylamino)ethyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f][1,4]-thiazepine-8-carboxylate; c. Ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-2,3,4, 5,6,9-hexahydro-7-methyl-pyrido[2,3-f][1,4]thiazepine-8-carboxylate; d. Ethyl 9-(2,3-dichlorophenyl)-1,1-dioxo-4-ethyl-2,3,4,5,6,9-hexahydro-7-methyl-pyrido-[2,3-f][1,4]thiazepine-8-carboxylate; e. Ethyl 9-(2,3-dichlorophenyl)-4,7-dimethyl,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f]-[1,4]thiazepine-8-carboxylate; f. Ethyl 4,7-dimethy-1,1-dioxo-2,3,4,5,6,9-hexahydro-9-(2,3,4,5,6-pentafluorophenyl)-pyrido [2,3-f][1,4]thiazepine-8-carboxylate; g. Ethyl 1,1-dioxo-2,3,4,5,6,9-hexahydro-7-methyl-9-(2,3,4,5,6-pentafluorophenyl)-pyrido[2,3-f] [1,4]thiazepine-8-carboxylate; h. Ethyl 1,1-dioxo-4-ethyl-2,3,4,5,6,9-hexahydro-7-methyl-9-(3-nitrophenyl)-pyrido[2,3-f][1,4]thiazepine-8-carboxylate; i. 2-Acetoxyethyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydro-pyrido[2,3-f][1,4]thiazepine-8-carboxylate; j. 2-Pivaloyloxyethyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f][1,4]thiazepine-8-carboxylate; k. 2-(N,N-dibenzylamino)ethyl 4-(2,3,dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f][1,4]thiazepine-8-carboxylate; l. 2-(N-benzyl-N-methylamino)ethyl 4-(2,3-dichlorophenyl)-4-ethyl- 1,1,-dioxo-2,3,4,5,6,9-hexahydro-7-methyl-pyrido[2,3-f][1,4] thiazepine-8-carboxylate; and m. (N-benzyl-2-pyrolidinyl)methyl 9-(2,3-dichlorophenyl)-4,7-dimethyl-1,1-dioxo-2,3,4,5,6,9-hexahydropyrido[2,3-f][1,4]-thiazepine-8-carboxylate. The compound of claim 1 selected from the group consisting of a. Ethyl 4-(2,3-dichlorophenyl)-5,5-dioxo-10-formyl-2-methyl-1,4,10,11-tetrahydropyrido-[3,2-b] [1,5]benzothiazepine-3-carboxylate; b. Ethyl 4-(2,3-dichlorophenyl)-2,10-dimethyl-5,5-dioxo-1,4,10,11-tetrahydropyrido[3,2-b] [1,5]benzothiazepine-3-carboxylate; c. 2-(N-benzyl-N-methylamino)ethyl 4-(2,3-dichlorophenyl)-2,10-dimethyl-5,5-dioxo-1,4,10,11-tetrahydropyrido[3,2-b] [1,5]-benzothiazepine-3-carboxylate. A pharmaceutical composition comprising as an active ingredient an effective amount of a compound of any one of claims 1 to 4 and a suitable pharmaceutical carrier. A process for synthesizing the compound of any one of claims 1 to 3 in which Y and Z are CH₂, comprising the steps of: a. treating cystamine dihydrochloride with di-t-butyl dicarbonate to produce bis N-( t -butyloxycarbonyl)-cystamine; b. treating said bis N-( t -butyloxy-carbonyl)-cystamine with NaBH₄ to produce N-( t -butyloxycarbonyl)-2-amino-ethane thiol; c. reacting said N-( t -butyloxycarbonyl)-2-aminoethane thiol with epichlorohydrin to produce an intermediate chlorohydrin of the formula d. cyclizing said intermediate chlorohydrin through an epoxide of the formula to produce a thiazepinol of the formula e. oxidizing said thiazepinol with m -chloroperoxybenzoic acid to produce 1,1-dioxo-thiazepinol; f. further oxidizing said 1,1-dioxo-thiazepinol with Jones reagent to produce a 1,1-dioxo-thiazepinone of the formula g. reacting said 1,1-dioxothiazepinone with an R₃-substituted aldehyde and a substituted 3-aminoacrylate derivative of the formula where R₁, R₂ and R₃ are as defined in claim 1, to produce a dihydropyridine of the formula where R₁, R₂, R₃and R₄ are as defined in claim 1. A process for synthesizing the compound of any one of claims 1, 2 or 4 in which Y and Z together form a phenyl ring, comprising the steps of: a. reacting a benzothiazepinone of the formula where R₄ is as defined in claim 1, with NaBH₄, m -chloroperoxybenzoic acid and Jones reagent to produce a 1,1-dioxo-benzothiazepenone of the formula where R₄ is as defined in claim 1; and b. reacting said 1,1-dioxo-benzothiazepenone with an R₃-substituted aldehyde and a substituted 3-aminoacrylate derivative of the formula where R₁, R₂ and R₃ are as defined in claim 1, to produce a dihydropyridine of the formula where R₁, R₂, R₃ and R₄ are as defined in claim 1. A compound of any one of claims 1 to 4 or a composition of claim 5, for use in treating cardiovascular disorders, including hypertension, ischemia, angina, congestive heart failure, migraine, myocardial infarction, stroke, hypersensitivity, allergy, asthma, dysmenorrhea, esophageal spasm, gastrointestinal motility disorders, glaucoma, premature labor or urinary tract disorders.

Inventors: DODD JOHN H, SCHWENDER CHARLES F, WUSTROW DAVID J, DODD, JOHN H., SCHWENDER, CHARLES F., WUSTROW, DAVID J.
Applicants: ORTHO PHARMA CORP, ORTHO PHARMACEUTICAL CORPORATION
Application year: 1991
Main classification: C07D513
IPC codes: A61P9, A61P13, A61K31, A61P43, A61P27, A61P37, A61P11, A61P15, A61P25, A61P1, C07D513